Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia

In brief

12 week study to assess the LDL-C lowering efficacy, other lipid and glycemic measures, and safety of bempedoic acid/ezetimibe FDC compared to ezetimibe and placebo in patients with type 2 diabetes (T2D) and elevated LDL-C

Key facts

Study ID
NCT03531905
Run by
Esperion Therapeutics, Inc.
People needed
242
Starts
2018-05-09
Expected to finish
2019-06-18
Last updated by the study team
2020-04-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.